GO:0072563 endothelial microparticle: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072563 endothelial microparticle is a blood microparticle derived from endothelial cells that carries membrane receptors and other endothelial proteins.
• Endothelial microparticles are released in response to shear stress, inflammation, and vascular injury, and serve as biomarkers of endothelial activation and dysfunction.
• They carry bioactive cargo such as protein disulfide isomerase (PDI) that can promote platelet activation in metabolic and cardiovascular disease.
• Endothelial microparticles can propagate viral infection and activate endothelium, as shown for varicella-zoster virus vasculopathy.
• Pharmacological agents such as tiotropium can inhibit proinflammatory microparticle generation by endothelial cells.
• Studying endothelial microparticles requires integrated approaches including flow cytometry, proteomics, and CRISPR-based gene editing to dissect cargo and receptor function.
Description
Endothelial microparticles (EMPs) are small membrane vesicles released from activated or apoptotic endothelial cells. They are classified under the Gene Ontology term GO:0072563 as a blood microparticle that is derived from, and contains membrane receptors as well as other proteins characteristic of, an endothelial cell. EMPs are increasingly recognized as both biomarkers and effectors of vascular pathology, reflecting endothelial activation and dysfunction in cardiovascular diseases. Their release is modulated by biomechanical forces such as shear stress, linking hemodynamic conditions to vesicle shedding. Beyond their diagnostic value, EMPs carry functional cargo including protein disulfide isomerase (PDI), which can amplify platelet activation in metabolic syndrome and diabetic coronary heart disease. They also participate in intercellular communication, as demonstrated by microparticle-mediated varicella-zoster virus propagation and endothelial activation. Understanding the composition, assembly, and regulation of EMPs is therefore critical for researchers in vascular biology, thrombosis, and inflammation. This article provides a research-grade overview of GO:0072563, integrating authoritative ontology data with published literature to guide experimental design and therapeutic targeting.
endothelial microparticle At A Glance
| GO ID | GO:0072563 |
|---|---|
| GO term | endothelial microparticle |
| Ontology | cellular_component |
| Synonym | none |
| Major function | Intercellular communication, biomarker of endothelial activation, and carrier of bioactive proteins such as PDI and membrane receptors |
| Derivation | Released from activated or apoptotic endothelial cells |
| Regulation | Shear stress and inflammatory stimuli modulate release |
| Pathological relevance | Cardiovascular diseases, metabolic syndrome, viral vasculopathy |
What Is GO:0072563?
According to the Gene Ontology, GO:0072563 endothelial microparticle is a blood microparticle that originates from an endothelial cell and contains membrane receptors and other proteins characteristic of endothelial cells. In other words, it is a subcellular vesicle shed from the endothelial plasma membrane that retains endothelial surface markers and bioactive molecules, distinguishing it from microparticles of platelet, leukocyte, or other cellular origin.
Why Is endothelial microparticle Important in Cell Biology?
Endothelial microparticles are important because they serve as accessible blood-borne indicators of endothelial health and actively contribute to vascular pathology. They are elevated in cardiovascular diseases and correlate with endothelial dysfunction, making them attractive biomarkers. Functionally, EMP-associated PDI can enhance platelet activation, linking them to thrombotic complications in metabolic syndrome and diabetic coronary heart disease. They also mediate viral propagation, as shown for varicella-zoster virus, thereby amplifying endothelial activation and vasculopathy. Moreover, their release is dynamically regulated by shear stress, positioning them as mechanosensitive effectors of vascular homeostasis. Pharmacological inhibition of microparticle generation, for example by tiotropium, highlights their potential as therapeutic targets. Thus, GO:0072563 represents a convergence point for thrombosis, inflammation, and infectious vascular disease research.
• Biomarker of endothelial activation and dysfunction in cardiovascular diseases.
• Carrier of protein disulfide isomerase that promotes platelet activation in metabolic syndrome.
• Mediator of platelet activation in diabetic coronary heart disease.
• Vehicle for varicella-zoster virus propagation and endothelial activation.
• Release is regulated by shear stress, linking hemodynamics to vesicle shedding.
• Target of anti-inflammatory drugs such as tiotropium that inhibit microparticle generation.
• Involved in intercellular communication within the vascular wall.
• Potential source of placenta-derived microparticles in pregnancy-related vascular biology.
• Useful for studying endothelial cell-derived vesicle cargo and receptor profiles.
• Provides a model to dissect mechanisms of vascular inflammation and thrombosis.
What Happens During endothelial microparticle?
Endothelial cell activation and vesiculation
In simple terms: Endothelial cells respond to stress by budding off small particles from their membrane.
Endothelial microparticles are generated when endothelial cells undergo activation or apoptosis in response to stimuli such as inflammatory cytokines, shear stress, or viral infection. This process involves cytoskeletal rearrangement and membrane blebbing, leading to the release of vesicles that carry endothelial surface receptors and cytoplasmic proteins. Shear stress is a key biomechanical regulator of this release, as demonstrated in cultured endothelial cells. The resulting microparticles retain characteristics of the parent endothelial cell, including membrane receptors and other proteins.
Cargo selection and protein disulfide isomerase association
In simple terms: The particles carry specific proteins, including an enzyme called PDI that can activate platelets.
Endothelial microparticles are not merely membrane fragments; they selectively incorporate bioactive molecules. Protein disulfide isomerase (PDI) has been identified on endothelial microparticles, where it contributes to platelet activation in metabolic syndrome and diabetic coronary heart disease. This cargo selection implies that microparticles can concentrate specific enzymes and receptors, thereby exerting functional effects on target cells. The presence of PDI on EMPs links them directly to thrombotic pathways.
Intercellular communication and viral propagation
In simple terms: Microparticles can transfer signals or even viruses from one cell to another.
Endothelial microparticles can act as vehicles for intercellular communication. In varicella-zoster virus (VZV) vasculopathy, microparticles mediate VZV propagation and endothelial activation, demonstrating that EMPs can carry infectious agents and amplify vascular inflammation. This mechanism highlights the role of EMPs beyond biomarkers, as active participants in disease pathogenesis. Pericyte secretome studies also suggest that vascular cells communicate via secreted factors and vesicles, including microparticles.
Regulation by pharmacological agents
In simple terms: Certain drugs can reduce the production of these particles.
The generation of proinflammatory microparticles by endothelial cells can be inhibited by pharmacological agents. Tiotropium, a long-acting muscarinic antagonist, inhibits proinflammatory microparticle generation by human bronchial and endothelial cells. This finding indicates that microparticle release is a regulated process amenable to therapeutic intervention. It also suggests that EMP levels can be modulated in inflammatory conditions, providing a potential strategy to reduce vascular inflammation.
Key Genes Involved in GO:0072563 endothelial microparticle
The following genes and proteins are associated with endothelial microparticle biology, based on published literature and their roles in endothelial activation, vesiculation, and cargo function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDI | Protein disulfide isomerase; promotes platelet activation when associated with EMPs | Target for antithrombotic strategies in metabolic syndrome and diabetic coronary heart disease |
| VZV | Varicella-zoster virus; propagates via EMPs and activates endothelium | Model for viral vasculopathy and EMP-mediated infection |
| ICAM-1 | Endothelial adhesion molecule; characteristic membrane receptor on EMPs | Marker of endothelial activation and EMP detection |
| VCAM-1 | Endothelial adhesion molecule; often present on EMPs | Biomarker of endothelial dysfunction |
| E-selectin | Endothelial activation marker; can be carried by EMPs | Indicator of inflammatory endothelial phenotype |
| CD31 (PECAM-1) | Endothelial junctional protein; characteristic of endothelial cells | Used to identify endothelial origin of microparticles |
| CD144 (VE-cadherin) | Endothelial-specific adhesion molecule | Marker for EMP characterization |
| CD62E (E-selectin) | Endothelial activation marker | Flow cytometry detection of EMPs |
| CD105 (endoglin) | Endothelial membrane receptor | EMP marker and angiogenesis-related |
| CD146 | Endothelial cell adhesion molecule | EMP marker and endothelial activation |
| Annexin V | Binds phosphatidylserine exposed on microparticles | Common reagent for microparticle detection |
| Rho kinase | Cytoskeletal regulator involved in membrane blebbing | Potential target to modulate EMP release |
| Caspase-3 | Apoptosis effector; contributes to microparticle formation | Studying apoptotic EMP generation |
| Tiotropium target (muscarinic receptors) | Inhibition of proinflammatory microparticle generation | Pharmacological modulation of EMP release |
| PDGFR | Pericyte signaling; may influence vascular microparticle crosstalk | Vascular cell communication |
| VEGF | Endothelial activation and permeability factor | Indirect regulator of EMP release |
| TNF-alpha | Proinflammatory cytokine; induces endothelial activation | Stimulus for EMP generation in vitro |
| Thrombin | Coagulation protease; activates endothelial cells | Inducer of EMP release |
How Is endothelial microparticle Regulated?
Endothelial microparticle release is regulated by biomechanical and biochemical stimuli. Shear stress is a major regulator, as demonstrated by Vion et al. (2013), who showed that shear stress modulates endothelial microparticle release in cultured endothelial cells. Inflammatory cytokines and viral infection can also trigger EMP generation. Pharmacological inhibition by tiotropium indicates that muscarinic receptor signaling contributes to proinflammatory microparticle production. Additionally, the cargo of EMPs, such as PDI, can be regulated at the level of protein incorporation, affecting downstream platelet activation. These regulatory layers provide multiple entry points for experimental manipulation.
endothelial microparticle and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDI | Metabolic syndrome and diabetic coronary heart disease; platelet activation | Endothelial cell culture with PDI knockout or overexpression; platelet aggregation assays |
| VZV | Varicella-zoster virus vasculopathy | Infection of endothelial cells with VZV; microparticle isolation and transfer experiments |
| ICAM-1 | Cardiovascular diseases; endothelial activation | Endothelial cells with ICAM-1 knockout; flow cytometry for EMP markers |
| VCAM-1 | Atherosclerosis and inflammation | VCAM-1 knockout endothelial cells; microparticle release assays |
| E-selectin | Inflammatory vascular diseases | E-selectin knockout or knockdown endothelial cells; EMP characterization |
Cardiovascular diseases and endothelial dysfunction
Endothelial microparticles are elevated in cardiovascular diseases and serve as biomarkers of endothelial activation and dysfunction. They reflect the extent of endothelial injury and predict adverse outcomes. Their cargo, including PDI, can promote platelet activation, contributing to thrombotic risk in diabetic coronary heart disease. Thus, EMPs are both markers and mediators of cardiovascular pathology.
Metabolic syndrome and thrombosis
In metabolic syndrome, endothelial microparticle-associated PDI promotes platelet activation, linking metabolic dysregulation to a prothrombotic state. This mechanism suggests that targeting EMP-PDI interactions could reduce thrombotic complications in patients with metabolic disorders. The presence of PDI on EMPs provides a direct molecular link between endothelial activation and platelet function.
Viral vasculopathy
Endothelial microparticles mediate varicella-zoster virus propagation and endothelial activation, contributing to VZV vasculopathy. This demonstrates that EMPs can serve as vehicles for viral dissemination within the vasculature, amplifying inflammation and injury. The study by Eleftheriou et al. (2020) highlights a novel mechanism of viral pathogenesis involving EMPs.
Pregnancy-related vascular biology
Placenta-derived microparticles, which share some characteristics with endothelial microparticles, are studied in the context of pregnancy complications. Although distinct, these microparticles illustrate the broader relevance of blood microparticles in vascular biology and potential crosstalk with endothelial cells.
From endothelial microparticle-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PDI on endothelial microparticles promote platelet activation? | PDI knockout endothelial cells; co-culture with platelets; platelet activation assays |
| How does shear stress regulate EMP release? | Endothelial cells exposed to controlled shear stress in microfluidic devices; EMP quantification |
| Can tiotropium inhibit EMP generation? | Endothelial cells treated with tiotropium; microparticle flow cytometry |
| Does VZV use EMPs to propagate? | VZV-infected endothelial cells; EMP transfer to naive cells; viral titration |
| What membrane receptors are characteristic of EMPs? | Endothelial cells with tagged receptors; proteomics of isolated EMPs |
| Can CRISPR knockout of candidate genes alter EMP cargo? | CRISPR knockout endothelial cell lines; EMP proteomics and functional assays |
How to Study the endothelial microparticle Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface markers and size of microparticles | Quantification of EMPs in plasma or culture supernatants |
| Mass spectrometry proteomics | Protein cargo of isolated EMPs | Identification of PDI and other bioactive proteins |
| Platelet aggregation assay | Platelet activation induced by EMPs | Testing thrombotic potential of EMP-PDI |
| Microfluidic shear stress | EMP release under flow | Studying mechanotransduction in endothelial cells |
| Viral titration | VZV propagation via EMPs | Investigating viral vasculopathy mechanisms |
| ELISA | Specific EMP markers or cargo proteins | Biomarker validation in clinical samples |
| Electron microscopy | Morphology and size of microparticles | Confirming vesicle structure |
| CRISPR knockout | Gene function in EMP biology | Dissecting candidate genes affecting EMP release or cargo |
Flow cytometry for microparticle detection
Flow cytometry is a standard method to identify and quantify endothelial microparticles based on size and surface markers such as CD31, CD144, CD62E, and Annexin V. This technique allows researchers to distinguish EMPs from microparticles of other cellular origins and to assess endothelial activation status. It is widely used in clinical studies to correlate EMP levels with cardiovascular disease.
Proteomics of isolated microparticles
Mass spectrometry-based proteomics can characterize the protein cargo of endothelial microparticles, including PDI and membrane receptors. This approach reveals potential bioactive molecules that mediate downstream effects such as platelet activation. Proteomic profiling of EMPs from different disease states can identify novel biomarkers and therapeutic targets.
Functional assays for platelet activation
To study the functional impact of EMP-associated PDI, researchers use platelet aggregation and activation assays. These assays measure platelet activation markers (e.g., P-selectin, integrin alphaIIbbeta3) after exposure to EMPs. Such experiments demonstrate causality between EMP cargo and thrombotic phenotypes.
Shear stress and pharmacological modulation
Microfluidic systems and cone-and-plate viscometers apply controlled shear stress to endothelial cells to study EMP release. Pharmacological agents like tiotropium can be tested for their ability to inhibit microparticle generation. These methods help dissect the biomechanical and biochemical regulation of EMP production.
How CRISPR Can Be Used to Study GO:0072563 endothelial microparticle
Knockout
CRISPR knockout of candidate genes in endothelial cells can determine their role in endothelial microparticle biogenesis and cargo loading. For example, knocking out PDI would test whether EMP-associated PDI is required for platelet activation. Knockout of adhesion molecules like ICAM-1 or VCAM-1 can reveal their contribution to EMP formation or function. This approach provides causal evidence in a clean genetic background.
Point Mutation
Point mutations can be introduced to dissect specific domains or residues critical for EMP biology. For instance, mutating the catalytic sites of PDI would test whether its enzymatic activity is required for platelet activation when carried by EMPs. Similarly, point mutations in receptor tyrosine kinases or adhesion molecules can clarify signaling events leading to vesiculation.
Knock-in
Knock-in of tagged proteins (e.g., GFP or HA) allows tracking of specific molecules during EMP formation and transfer. Tagging PDI or endothelial markers can enable visualization of their incorporation into microparticles and their delivery to target cells. Knock-in of reporter genes under endogenous promoters can also monitor endothelial activation states that trigger EMP release.
Overexpression
Overexpression of candidate genes in endothelial cells can test sufficiency for EMP production or cargo enrichment. For example, overexpressing PDI may increase EMP-associated PDI and enhance platelet activation. Overexpressing viral proteins or receptors could mimic pathological states such as VZV infection. This approach complements loss-of-function studies.
How EDITGENE Supports endothelial microparticle Research
Researchers studying endothelial microparticle-related genes often need to determine whether a candidate gene is causally involved in vesicle biogenesis, cargo selection, or downstream effects on platelets and other vascular cells. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for endothelial microparticle research.
Frequently Asked Questions About endothelial microparticle
What is an endothelial microparticle?
An endothelial microparticle is a small vesicle released from endothelial cells that contains membrane receptors and other endothelial proteins, classified under GO:0072563.
What genes are involved in endothelial microparticle biology?
Genes include PDI, ICAM-1, VCAM-1, E-selectin, CD31, CD144, and others that contribute to endothelial activation and vesicle cargo.
How are endothelial microparticles detected?
They are commonly detected by flow cytometry using markers such as CD31, CD144, CD62E, and Annexin V.
What diseases are associated with endothelial microparticles?
They are associated with cardiovascular diseases, metabolic syndrome, diabetic coronary heart disease, and viral vasculopathy.
Do endothelial microparticles promote blood clotting?
Yes, EMP-associated protein disulfide isomerase can promote platelet activation, contributing to thrombosis in metabolic syndrome and diabetic coronary heart disease.
Can endothelial microparticle release be inhibited?
Yes, tiotropium has been shown to inhibit proinflammatory microparticle generation by human endothelial cells.
How does shear stress affect endothelial microparticles?
Shear stress regulates endothelial microparticle release, as demonstrated in cultured endothelial cells.
What is the role of endothelial microparticles in viral infections?
They can mediate varicella-zoster virus propagation and endothelial activation, contributing to VZV vasculopathy.
How can CRISPR be used to study endothelial microparticles?
CRISPR knockout, point mutation, knock-in, and overexpression can dissect gene function in EMP biogenesis, cargo, and downstream effects.
What are the research methods for studying endothelial microparticles?
Methods include flow cytometry, proteomics, platelet activation assays, shear stress models, and CRISPR screens.
Conclusion
GO:0072563 endothelial microparticle represents a critical component of vascular biology, serving as both a biomarker and a mediator of endothelial dysfunction, thrombosis, and viral pathogenesis. The integration of QuickGO ontology data with published literature highlights the importance of EMP cargo, particularly PDI, in platelet activation and disease. Advances in CRISPR-based gene editing and multi-omics approaches will continue to unravel the molecular mechanisms governing EMP biogenesis and function. Targeting EMPs or their cargo may offer novel therapeutic strategies for cardiovascular and inflammatory diseases.
References
- 1. Zhang J. 2022. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases.. Rev Cardiovasc Med 23(2):73 PMID: 35229564
- 2. Eleftheriou D et al.. 2020. Microparticle-mediated VZV propagation and endothelial activation: Mechanism of VZV vasculopathy.. Neurology 94(5):e474-e480 PMID: 31892634
- 3. Sun XD et al.. 2021. Endothelial microparticle-associated protein disulfide isomerase increases platelet activation in diabetic coronary heart disease.. Aging (Albany NY) 13(14):18718-18739 PMID: 34285139
- 4. Gaceb A et al.. 2018. Pericyte Secretome.. Adv Exp Med Biol 1109:139-163 PMID: 30523595
- 5. Neri T et al.. 2019. Tiotropium inhibits proinflammatory microparticle generation by human bronchial and endothelial cells.. Sci Rep 9(1):11631 PMID: 31406171
- 6. Fan GQ et al.. 2016. Endothelial cells microparticle-associated protein disulfide isomerase promotes platelet activation in metabolic syndrome.. Oncotarget 7(50):83231-83240 PMID: 27825126
- 7. Vion AC et al.. 2013. Shear stress regulates endothelial microparticle release.. Circ Res 112(10):1323-33 PMID: 23536307
- 8. Aharon A et al.. 2013. Placenta-derived microparticles.. Thromb Res 131 Suppl 1:S22-4 PMID: 23452734
